The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Judo Bio Appoints Rajiv Patni As Chief Executive Officer
PRIVATEOct 07, 2024•over 1 year ago
Position
Chief Executive Officer
Company
Judo Bio
Rajiv Patni
CambridgeBiotechnology
Description
Judo Bio announced the appointment of biopharma industry veteran Rajiv Patni, M.D., as the company’s Chief Executive Officer and Board director. The company has secured $100 million in initial financing, including seed financing and Series A, to advance lead ligand-siRNA conjugate to the clinic and to further build the company’s proprietary STRIKE platform.
Company Information
Company
Judo Bio
Location
300 TECHNOLOGY SQUARE
Cambridge, Massachusetts, United States
About
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.
CambridgeBiotechnology